Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Arena Pharmaceuticals, Inc.    ARNA

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Arena Pharmaceuticals, Inc. : Five Star Equities Issues New Research Reports on ARNA, DD, KR and VECO

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/17/2013 | 03:05pm CEST

Five Star Equities releases regular market updates so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.FiveStarEquities.com and get exclusive access to our numerous stock reports.

Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) shares hit a low of $7.70 Friday before settling to close at $7.78, a decrease of 6.71 percent. The stock traded in between $7.70 to $8.30 on volume of 8.97 million shares traded. Consumer Reports has recently advised their readers to ?skip? Arena?s weight loss drug, Belviq.

Get more information on Arena Pharmaceuticals and free access to the in-depth equity report at:
www.FiveStarEquities.com/ARNA

E I Du Pont De Nemours And Co (NYSE: DD) shares hit a low of $52.16 Friday before settling to close at $52.68, a decrease of 2.23 percent. The stock traded in between $52.16 to $53.70 on volume of 11.28 million shares traded. Jefferies Group currently has a ?hold? rating on the stock and has recently raised its price target on the company to $56.00 from $52.00.

Get more information on Du Pont and free access to the in-depth equity report at:
www.FiveStarEquities.com/DD

The Kroger Co. (NYSE: KR) hit a low of $34.67 Friday before settling to close at $34.79, a decrease of 0.77 percent. The stock traded in between $34.67 to $35.25 on volume of 2.46 million shares traded. Argus currently has a ?buy? rating on the stock and has recently raised its price target on the company to $40.00 from $34.00.

Get more information on Kroger and free access to the in-depth equity report at:
www.FiveStarEquities.com/KR

Veeco Instruments Inc. (NASDAQ: VECO) shares hit a low of $37.74 Friday before settling to close at $38.10, a decrease of 3.20 percent. The stock traded in between $37.74 and $39.04 on volume of 559,990 shares traded. UBS has reiterated it ?neutral? view on the company due to pricing pressure pricing pressure Veeco?s metal organic vapor deposition epitaxial systems.

Get more information on Veeco Instruments and free access to the in-depth equity report at:
www.FiveStarEquities.com/VECO

Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Wall Street Fundamentals has no financial relationship with any company whose stock is mentioned in this release.

Contact:
Five Star Equities
[email protected]


© Accesswire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ARENA PHARMACEUTICALS, INC
05/22 ARENA PHARMACEUTICALS, INC. : Today's Research Reports on Biotech Stocks to Watc..
05/18 ARENA PHARMACEUTICALS : to Host Key Opinion Leader Event on Pulmonary Arterial H..
05/16 ARENA PHARMACEUTICALS : to Present Phase 1 Data on Ralinepag for Treatment of Pu..
05/15 INSIDER TRADING ACTIVITY ARENA PHARM : ARNA) – Insider Bought 25,000 share..
05/10 ARENA PHARMACEUTICALS, INC. (NASDAQ : ARNA) reported earnings of ($0.09) per sha..
05/09 ARENA PHARMACEUTICALS : reports 1Q loss
05/09 ARENA PHARMACEUTICALS : Management's Discussion and Analysis of Financial Condit..
05/09 ARENA PHARMACEUTICALS INC : Results of Operations and Financial Condition, Finan..
05/09 ARENA PHARMACEUTICALS : Provides Corporate Update and Reports First Quarter 2017..
05/09 ARENA PHARMACEUTICALS, INC. : Investor Network: Arena Pharmaceuticals, Inc. to H..
More news
Sector news : Biotechnology & Medical Research - NEC
05/23 UK competition watchdog accuses Merck of obstructing biosimilars
05/22 Cross-border M&A between U.S. and European firms at 10 year high
05/22DJAMGEN : Another Gloomy Day for Amgen
05/09 Sanofi pegs U.S. drug price rises to below healthcare inflation
05/09DJVERTEX PHARMACEUTICALS INCORPORATED : Trump's Pick to Lead FDA Has Backing of Bi..
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
05/19 Leerink likes Arena, sees almost 300% upside; shares up 10%
05/19 PREMARKET GAINERS AS OF 9 : 05 am
05/13 THE OBESITY EPIDEMIC : Are Roche And Bristol-Myers Sitting On A Mighty Prospect?
05/10 Commentary On Great Point Partners' Positions Part 1
05/09 Arena Pharmaceuticals misses by $0.02, misses on revenue
Advertisement
Financials ($)
Sales 2017 22,8 M
EBIT 2017 -84,1 M
Net income 2017 -90,0 M
Finance 2017 52,0 M
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales 2017 16,4x
EV / Sales 2018 15,9x
Capitalization 425 M
More Financials
Chart ARENA PHARMACEUTICALS, INC
Duration : Period :
Arena Pharmaceuticals, Inc Technical Analysis Chart | ARNA | US0400471027 | 4-Traders
Full-screen chart
Technical analysis trends ARENA PHARMACEUTI...
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Average target price 3,38 $
Spread / Average Target 152%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Amit D. Munshi President, Chief Executive Officer & Director
Tina Susan Nova Chairman
Craig M. Audet SVP-Operations & Head-Global Regulatory Affairs
Kevin R. Lind Chief Financial Officer & Executive Vice President
John Adams Head-Scientific Affairs
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ARENA PHARMACEUTICALS,..-5.63%425
INCYTE CORPORATION34.07%27 528
QUINTILES IMS HOLDINGS..9.20%18 382
LONZA GROUP AG18.67%15 234
CELLTRION, INC.--.--%10 254
SEATTLE GENETICS, INC.26.21%9 492
More Results